Organogenesis Holdings Inc is a leading regenerative medicine company that focuses on developing and commercializing advanced wound care and surgical biologics products
The company specializes in innovative solutions that support the healing of complex wounds and surgical procedures, leveraging its expertise in cellular and tissue-based therapies. Organogenesis is committed to improving patient outcomes by offering cutting-edge products that foster healing and recovery, thereby addressing unmet medical needs in the healthcare sector. Through a combination of research, development, and clinical support, the company aims to enhance the quality of care provided to patients across various medical disciplines.
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
Shares of Reneo Pharmaceuticals, Inc. (NASDAQRPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share. Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
